IL299505A - vector - Google Patents

vector

Info

Publication number
IL299505A
IL299505A IL299505A IL29950522A IL299505A IL 299505 A IL299505 A IL 299505A IL 299505 A IL299505 A IL 299505A IL 29950522 A IL29950522 A IL 29950522A IL 299505 A IL299505 A IL 299505A
Authority
IL
Israel
Prior art keywords
promoter
viral vector
seq
sequence identity
aav
Prior art date
Application number
IL299505A
Other languages
English (en)
Hebrew (he)
Original Assignee
Syncona Investment Man Limited
Univ Bristol
Purespring Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncona Investment Man Limited, Univ Bristol, Purespring Therapeutics Ltd filed Critical Syncona Investment Man Limited
Publication of IL299505A publication Critical patent/IL299505A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Image Analysis (AREA)
  • Devices For Executing Special Programs (AREA)
IL299505A 2020-06-30 2021-06-30 vector IL299505A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2010009.5A GB202010009D0 (en) 2020-06-30 2020-06-30 Vector
PCT/GB2021/051668 WO2022003357A1 (en) 2020-06-30 2021-06-30 Vector

Publications (1)

Publication Number Publication Date
IL299505A true IL299505A (en) 2023-02-01

Family

ID=71949697

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299505A IL299505A (en) 2020-06-30 2021-06-30 vector

Country Status (12)

Country Link
US (1) US20230175016A1 (https=)
EP (1) EP4172345A1 (https=)
JP (1) JP2023536008A (https=)
KR (1) KR20230056658A (https=)
CN (1) CN115997025A (https=)
AU (1) AU2021300616A1 (https=)
BR (1) BR112022026521A2 (https=)
CA (1) CA3183830A1 (https=)
GB (1) GB202010009D0 (https=)
IL (1) IL299505A (https=)
MX (1) MX2022016101A (https=)
WO (1) WO2022003357A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
AU2021293174A1 (en) 2020-06-14 2023-01-19 Vertex Pharmaceuticals Incorporated Complement Factor I-related compositions and methods
GB202217332D0 (en) * 2022-11-18 2023-01-04 Univ Bristol Methods
EP4410988A1 (en) * 2023-01-31 2024-08-07 Universitätsklinikum Hamburg-Eppendorf An aav2-vector variant for targeted transfer of genes
WO2024178007A1 (en) * 2023-02-21 2024-08-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Mafb promoter for gene therapy for diabetes
GB202304841D0 (en) * 2023-03-31 2023-05-17 Purespring Therapeutics Ltd Promoter
AU2024262827A1 (en) * 2023-04-27 2025-10-16 Oregon Health & Science University Kidney-targeting aav capsids and methods of use thereof
GB202414499D0 (en) * 2024-10-02 2024-11-13 Purespring Therapeutics Ltd Methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL332875A1 (en) 1996-10-17 1999-10-25 Oxford Biomedica Ltd Retroviral vectors
WO2005012351A2 (en) * 2003-08-01 2005-02-10 The Brigham And Women's Hospital, Inc. Novel functions for decay accelerating factor (daf) in inflammation
EP2357254A1 (en) * 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
ES2457822T3 (es) * 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
ES2857773T5 (es) * 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
CN108291216B (zh) * 2015-09-24 2022-09-16 宾夕法尼亚州大学信托人 用于治疗补体介导的疾病的组合物和方法
JP7222075B2 (ja) * 2018-09-13 2023-02-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット

Also Published As

Publication number Publication date
GB202010009D0 (en) 2020-08-12
CA3183830A1 (en) 2022-01-06
KR20230056658A (ko) 2023-04-27
MX2022016101A (es) 2023-06-01
EP4172345A1 (en) 2023-05-03
AU2021300616A1 (en) 2023-01-19
US20230175016A1 (en) 2023-06-08
BR112022026521A2 (pt) 2023-01-31
WO2022003357A1 (en) 2022-01-06
JP2023536008A (ja) 2023-08-22
CN115997025A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
IL299505A (en) vector
EP4305181B1 (en) Minimal nephrin promoter
WO2019068854A1 (en) GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
US20220133912A1 (en) Gene Therapy
KR20240053630A (ko) 오토페를린의 이소형 5를 인코딩하는 이중 재조합 aav8 벡터 시스템 및 이의 용도
US20230392164A1 (en) Dual expression vector for gene augmentation for crumbs complex homologue 1 (crb1) mutations
WO2018148743A1 (en) Modulation of ischemic cell bioenergetics
US20260053952A1 (en) Methods of delivering a viral vector to a kidney
JP2024504625A (ja) 疾患の治療および核酸送達の改善
RU2854890C1 (ru) Вектор
US20240115737A1 (en) Gene therapy for dopamine transporter deficiency syndrome
CN117897399A (zh) 突变的膜联蛋白a5多肽及其在治疗目的中的用途
TW202216186A (zh) 用於治療同種異體移植物血管病變之組成物與方法
US8545834B2 (en) G-substrate for the treatment and prevention of parkinson's disease
Mason SRSF1-mediated gene therapy as a therapeutic approach for C9ORF72-related amyotrophic lateral sclerosis and fronto-temporal dementia (ALS-FTD)
HK40096493A (zh) Danon病和其它自噬障碍的治疗方法
US20230330266A1 (en) Gene therapy for lipodystrophy
WO2025003703A1 (en) Promoters
AU2024306574A1 (en) Regulatory elements
Wu Delivery of Helper-Dependent Adenoviral Vectors to the Subretinal Space of Mice
Haire Gene therapy restores function to cone cells in an animal model of Leber congenital amaurosis (LCA-1)